Global Fertility Services Market (2024 Edition): Analysis By Gender (Male, Female), Treatment Type, Channel, Services , By Region, By Country: Market Insights and Forecast (2020-2030)
Global Fertility Services Market (2024 Edition): Analysis By Gender (Male, Female), Treatment Type (Medicines, Surgical Procedures, and Assisted Conception), Channel (Fertility Clinics, Hospitals, Research Institutes, and Others), Services (IVF, Genetic Testing, and Reproductive Tissue Storage and Donor Services), By Region, By Country: Market Insights and Forecast (2020-2030)
Azoth Analytics has released a research report titled “Global Fertility Services Market (2024 Edition)” which provides a complete analysis of the Global Fertility Services industry in terms of market segmentation By Gender (Male, Female), Treatment Type (Medicines, Surgical Procedures, and Assisted Conception), Channel (Fertility Clinics, Hospitals, Research Institutes, and Others), Services (IVF, Genetic Testing, and Reproductive Tissue Storage and Donor Services) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.
The report analyses the Fertility Services Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, South Korea, India). Millions of people face catastrophic healthcare costs after seeking treatment for infertility, making this a major equity issue and all too often, a medical poverty trap for those affected. Better policies and public financing can significantly improve access to treatment and protect poorer households from falling into poverty as a result. While assisted reproduction technologies (ART) have been available for more than three decades, with more than 5 million children born worldwide from ART interventions such as in vitro fertilization (IVF), these technologies are still largely unavailable, inaccessible and unaffordable in many parts of the world, particularly in low and middle-income countries (LMIC). Additionally, government policies could mitigate the many inequities in access to safe and effective fertility care.
Infertility is a disease of the male or female reproductive system defined by the failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. Infertility affects millions of people – and has an impact on their families and communities. Estimates suggest that approximately one in every six people of reproductive age worldwide experience infertility in their lifetime.
In the male reproductive system, infertility is most commonly caused by problems in the ejection of semen, absence or low levels of sperm, or abnormal shape (morphology) and movement (motility) of the sperm. In the female reproductive system, infertility may be caused by a range of abnormalities of the ovaries, uterus, fallopian tubes, and the endocrine system, among others. Infertility can be primary or secondary. Primary infertility is when a pregnancy has never been achieved by a person, and secondary infertility is when at least one prior pregnancy has been achieved.
Fertility care encompasses the prevention, diagnosis and treatment of infertility. Equal and equitable access to fertility care remains a challenge in most countries; particularly in low and middle-income countries. Fertility care is rarely prioritized in national universal health coverage benefit packages.
Availability, access, and quality of interventions to address infertility remain a challenge in most countries. Diagnosis and treatment of infertility is often not prioritized in national population and development policies and reproductive health strategies and are rarely covered through public health financing. Moreover, a lack of trained personnel and the necessary equipment and infrastructure, and the currently high costs of treatment medicines, are major barriers even for countries that are actively addressing the needs of people with infertility.
To effectively address infertility, health policies need to recognize that infertility is a disease that can often be prevented, thereby mitigating the need for costly and poorly accessible treatments. Incorporating fertility awareness in national comprehensive sexuality education programmes, promoting healthy lifestyles to reduce behavioural risks, including prevention, diagnosis and early treatment of STIs, preventing complications of unsafe abortion, postpartum sepsis and abdominal/pelvic surgery, and addressing environmental toxins associated with infertility, are policy and programmatic interventions that all governments can implement.
In addition, enabling laws and policies that regulate third party reproduction and ART are essential to ensure universal access without discrimination and to protect and promote the human rights of all parties involved. Once fertility policies are in place, it is essential to ensure that their implementation is monitored, and the quality of services is continually improved.
Scope of the Report:
- The report analyses the Fertility Services Market by Value (USD Million).
- The report presents the analysis of Fertility Services Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
- The report analyses the Fertility Services Market By Gender (Male, Female).
- The report analyses the Fertility Services Market Treatment Type (Medicines, Surgical Procedures, and Assisted Conception).
- The report also studies the Fertility Services Market By Channel (Fertility Clinics, Hospitals, Research Institutes, and Others) and By Services (IVF, Genetic Testing, and Reproductive Tissue Storage and Donor Services).
- The key insights of the report have been presented through the frameworks of SWOT Analysis. Also, the attractiveness of the market has been presented by region, By Gender, By Treatment Type, By Channel, & By Services.
- Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Virtus Health, CooperSurgical, Inc., Vitrolife, CARE Fertility, INVO Bioscience, Monash IVF, Carolinas Fertility Institute, Ferring B. V, IVIRMA Global, Apricity Fertility Clinic.